The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Heymsfield said more data are needed on whether the safety profile of semaglutide 7.2 mg differs from the 2.4 mg dose. Steven B. Heymsfield “The question is if that extra weight loss is worth th ...

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Further, 33.2% of patients on the highest semaglutide dose achieved weight loss of at least 25% after the 72-week mark, versus 16.7% of patients on semaglutide 2.4 mg and 0% of patients on placebo ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients ... the active ingredient semaglutide, are expected to ...

Semaglutide 7.2 mg achieved 20.7% weight ... Also Read: Novo Nordisk’s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges The trial included 1,407 randomized adults with obesity.

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...